BIO-TECHNE Business Summary

```json {"business_summary": "Bio-Techne Corp (TECH) operates a high-margin life sciences model centered on the development, manufacture, and sale of consumable reagents, analytical instruments, and clinical diagnostic tools. The company generates revenue through two primary segments: Protein Sciences, which provides specialized proteins, antibodies, and proteomic analytical platforms like the Ella and Maurice systems, and Diagnostics and Spatial Biology, which offers spatial genomics platforms (e.g., COMET) and clinical molecular diagnostics. As of early 2026, the company has pivoted toward four high-growth verticals—cell therapy, proteomic instrumentation, spatial biology, and precision diagnostics—which now account for nearly half of total revenue. Bio-Techne competes directly with industry giants such as Danaher (specifically its Cytiva division), Thermo Fisher Scientific, Bruker, and Agilent Technologies, positioning itself as a specialized, high-density provider of essential biological "raw materials" and automated protein analysis solutions that bridge the gap between basic research and clinical application.\n\nFounded in 1981 by Dr. Roger Lucas, Bio-Techne is currently led by President and CEO Kim Kelderman, who brought extensive operational experience from Thermo Fisher Scientific and Becton Dickinson upon his appointment in 2024. The executive team includes EVP and CFO James T. Hippel, formerly of Mirion Technologies and Thermo Fisher, and CTO Gary Latham, a veteran of Asuragen and Ambion who spearheads the company’s genomic and molecular innovation. The leadership is further supported by Will Geist, President of Protein Sciences, and Steve Crouse, who transitions to President of Diagnostics and Spatial Biology in March 2026. The Board of Directors, chaired by Robert V. Baumgartner, features high-pedigree industry experts including Dr. Rupert Vessey (Flagship Pioneering) and Dr. Judith Klimovsky (Genmab). The company maintains a robust institutional investor base, with approximately 99% of shares held by major financial entities, reflecting strong market confidence in its long-term growth strategy."} ```